Stock Analiz

Travere Therapeutics, Inc. (TVTX) financials: revenue, earnings and cash flow

Fiscal 2016–2025 + TTM · from SEC filings · data as of November 16, 2026

Summary

Travere Therapeutics’s revenue went from $134M in fiscal 2016 to $491M in fiscal 2025, growth of about 15.6% a year.

Net income in fiscal 2025 was -$26M, a net margin of -5.2%; the highest of the period.

Over the twelve months to September 30, 2026, revenue was $651M and net income -$122M.

The diluted share count rose 133% over the period (dilution).

Revenue, profit and cash flow by year

Revenue
2016: $134M162017: $155M172018: $164M182019: $175M192020: $198M202021: $132M212022: $109M222023: $145M232024: $233M242025: $491M25$491M
Net income
2016: -$48M162017: -$60M172018: -$103M182019: -$146M192020: -$169M202021: -$180M212022: -$278M222023: -$111M232024: -$322M242025: -$26M25-$26M
Free cash flow
2016: -$5M20162017: $7M20172018: -$26M20182019: -$58M20192020: -$50M20202021: -$20M20212022: -$186M20222023: -$281M2023-$281M
EPS (diluted)
2016: $-1.29162017: $-1.54172018: $-2.54182019: $-3.46192020: $-3.56202021: $-3.01212022: $-4.37222023: $-1.50232024: $-4.08242025: $-0.2925$-0.29

Income statement

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$651M$491M$233M$145M$109M$132M$198M$175M$164M$155M$134M
Gross profit$641M$480M$225M$134M$105M$128M$192M$170M$159M$151M$129M
Operating income-$133M-$63M-$324M-$388M-$320M-$199M-$176M-$137M-$80M-$54M-$58M
Net income-$122M-$26M-$322M-$111M-$278M-$180M-$169M-$146M-$103M-$60M-$48M
EPS (diluted)$-1.29$-0.29$-4.08$-1.50$-4.37$-3.01$-3.56$-3.46$-2.54$-1.54$-1.29
R&D$246M$206M$217M$245M$8M$201M$132M$141M$124M$78M$71M
Revenue growth—+110.5%+60.6%+32.7%−17.0%−33.5%+13.1%+6.8%+6.0%+16.0%+33.7%

Cash flow

Fiscal yearTTM2025202420232022202120202019201820172016
Operating cash flow$177M$38M-$237M-$280M-$186M-$15M-$43M-$58M-$25M$7M-$3M
Capital spending-$204M——-$668000-$191000-$5M-$7M-$195000-$727000-$887000-$1M
Free cash flow-$27M——-$281M-$186M-$20M-$50M-$58M-$26M$7M-$5M
Dividends paid—$0$0$0$0$0$0$0$0$0$0
Buybacks——————————$0
Stock-based pay$73M$45M$37M$44M$38M$30M$24M$21M$20M$27M$29M

Balance sheet

Fiscal yearTTM2025202420232022202120202019201820172016
Cash—$238M$59M$307M$347M$428M$357M$272M$311M$223M$41M
Debt—$329M$333M$405M$407M$262M$244M$215M$206M$45M$44M
Equity—$115M$59M$201M$43M$302M$211M$221M$318M$293M$308M
Total assets—$605M$594M$789M$673M$777M$607M$605M$709M$520M$525M
Shares (diluted)95M89M79M74M64M60M48M42M40M39M38M

Margins and returns

Fiscal yearTTM2025202420232022202120202019201820172016
Gross margin98.5%97.9%96.7%92.1%96.0%97.1%96.9%97.0%96.6%97.7%96.6%
Operating margin-20.5%-12.8%-138.9%-267.2%-292.2%-151.3%-88.8%-78.3%-48.7%-34.7%-43.6%
Net margin-18.7%-5.2%-137.9%-76.7%-254.4%-136.6%-85.4%-83.5%-62.5%-38.6%-35.9%
FCF margin-4.2%——-193.3%-170.4%-15.1%-25.0%-33.3%-15.6%4.2%-3.6%
ROIC—-11.2%-65.3%-50.6%-56.1%-27.9%-34.7%-31.5%-12.0%-12.6%-13.8%
ROE—-22.2%-544.3%-55.5%-649.9%-59.6%-80.2%-66.2%-32.3%-20.4%-15.6%

Frequently asked questions

What is Travere Therapeutics’s annual revenue?

$491M in fiscal 2025 and $651M over the twelve months to September 30, 2026.

How much profit does Travere Therapeutics make?

Net income was -$26M in fiscal 2025 (net margin -5.2%).

Is Travere Therapeutics’s revenue growing?

Yes: revenue rose 110.5% in fiscal 2025 compared with the year before.

From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.